Bellerophon Therapeutics, Inc. (BLPH) Analysts See $-0.12 EPS

October 13, 2018 - By Michael Collier

Bellerophon Therapeutics, Inc. (NASDAQ:BLPH) Logo

Analysts expect Bellerophon Therapeutics, Inc. (NASDAQ:BLPH) to report $-0.12 EPS on November, 6.They anticipate $0.10 EPS change or 45.45 % from last quarter’s $-0.22 EPS. After having $-0.20 EPS previously, Bellerophon Therapeutics, Inc.’s analysts see -40.00 % EPS growth. The stock increased 4.81% or $0.05 during the last trading session, reaching $1.09. About 169,000 shares traded. Bellerophon Therapeutics, Inc. (NASDAQ:BLPH) has risen 1.80% since October 13, 2017 and is uptrending. It has underperformed by 13.82% the S&P500.

Bellerophon Therapeutics, Inc., a clinical-stage therapeutics company, focuses on the development of products at the intersection of drugs and devices that address unmet medical needs in the treatment of cardiopulmonary diseases. The company has market cap of $63.00 million. The Company’s product candidates are INOpulse, a pulsatile nitric oxide delivery device, which is in Phase III clinical trials for the treatment of pulmonary arterial hypertension; and in Phase II clinical trials to treat pulmonary hypertension associated with chronic obstructive pulmonary diseases and pulmonary hypertension associated with idiopathic pulmonary fibrosis. It currently has negative earnings.

More news for Bellerophon Therapeutics, Inc. (NASDAQ:BLPH) were recently published by:, which released: “Bellerophon Therapeutics (BLPH) Updates INOpulse Phase 2b Clinical Program” on October 09, 2018.‘s article titled: “Bellerophon Therapeutics: INOpulse Gets A Shot At Redemption” and published on September 17, 2018 is yet another important article.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.